# JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy

> **NCT05164848** · PHASE1 · UNKNOWN · sponsor: **Peking University** · enrollment: 50 (estimated)

## Conditions studied

- Esophageal Squamous Carcinoma

## Interventions

- **DRUG:** JMT101
- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT05164848
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-25
- **Primary completion:** 2023-10
- **Final completion:** 2023-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2021-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05164848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05164848, "JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05164848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*